Forum

Your browser does not seem to support JavaScript. As a result, your viewing experience will be diminished, and you have been placed in read-only mode.

Please download a browser that supports JavaScript, or enable it if it's disabled (i.e. NoScript).

The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

763 - When and why was the following removed from the PAAB code? Disease information materials which make no mention of treatment by name, class, or category AND are not linked to healthcare product advertising in any way, are exempt from PAAB preclearance. Does it not still apply?

FYI post-approval change/preclearance exemption/what requires review/PAAB scope

1 Posts 1 Posters 904 Views 1 Watching

J Offline
J Offline
Jennifer Carroll

wrote on last edited by

#1

The code has been revised through stakeholder consultations, to be a succinct outline of pharmaceutical advertising standards. As the above copy was redundant copy (see The Distinction Between Advertising and Other Activities document) it was removed. The concept still applies.
1 Reply Last reply

0